Phase II Trial of Zemplar (19-Nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer.

Trial Profile

Phase II Trial of Zemplar (19-Nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 31 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top